论文部分内容阅读
目的:评价拉米夫定联合阿德福韦酯治疗老年失代偿期乙肝后肝硬化的临床疗效。方法:选取我院2014年6月-2016年6月收治的140例老年失代偿期乙肝后肝硬化患者,按照患者入院的先后顺序,分成观察组和对照组,各70例。观察组通过拉米夫定、阿德福韦酯联合治疗,对照组通过拉米夫定治疗,对比两组临床疗效。结果:观察组和对照组的HBV DNA阴转率分别为84.29%、52.86%,差异具有统计学意义,P<0.05。两组肝功能变化情况比较,P<0.05。结论:老年失代偿期乙肝后肝硬化,采取拉米夫定、阿德福韦酯联合治疗,可在较短的时间抑制并对,有效的改善患者的肝功能。
Objective: To evaluate the clinical efficacy of lamivudine combined with adefovir dipivoxil in the treatment of liver cirrhosis after decompensation in elderly patients. Methods: A total of 140 elderly patients with decompensated hepatitis B cirrhosis who were admitted to our hospital from June 2014 to June 2016 were selected and divided into observation group and control group, with 70 cases in each group. The observation group through lamivudine, adefovir dipivoxil combination therapy, the control group by lamivudine treatment, the clinical efficacy of the two groups were compared. Results: The negative conversion rates of HBV DNA in the observation group and the control group were 84.29% and 52.86%, respectively, with statistical significance (P <0.05). Changes in liver function between the two groups, P <0.05. Conclusion: The elderly patients with decompensated hepatitis B cirrhosis, lamivudine, adefovir dipivoxil combination therapy can be suppressed in a relatively short period of time and effective in improving the patient’s liver function.